Lazo de la Vega Lorena, Hovelson Daniel H, Cani Andi K, Liu Chia-Jen, McHugh Jonathan B, Lucas David R, Thomas Dafydd G, Patel Rajiv M, Tomlins Scott A
Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
Michigan Center for Translational Pathology, Department of Computational Medicine & Bioinformatics, University of Michigan Medical School, Ann Arbor, MI 48109.
Hum Pathol. 2016 Dec;58:161-170. doi: 10.1016/j.humpath.2016.09.004. Epub 2016 Sep 21.
Gene fusions between CIC and DUX4 define a rare class of soft tissue sarcomas poorly understood at the molecular level. Previous karyotyping and fluorescence in situ hybridization studies support chromosome 8 trisomy as a recurrent alteration; however, other driving alterations are largely unknown. Thus, we analyzed 11 formalin-fixed, paraffin-embedded CIC-DUX4 sarcoma tissue samples (including 3 sample pairs) using targeted Ion Torrent-based multiplexed polymerase chain reaction next-generation sequencing to characterize potential somatic driver alterations in 409 genes. Although we did not identify recurrent somatic mutations (point mutations or insertions/deletions), copy number analysis showed recurrent, broad copy number alterations, including gain of chromosome 8 and loss of 1p. In one sample pair (untreated primary and local recurrence resections), we identified similar copy number profiles and a somatic ARID1A R963X nonsense mutation exclusively in the local recurrence sample. In another sample pair (pre- and post-radiation treatment specimens), we observed single-copy loss of chromosome 7q exclusively in the posttreatment recurrence sample, supporting it as an acquired event after radiation treatment. In the last sample pair (near-concurrent, postchemotherapy primary and distant metastasis), molecular profiles were highly concordant, consistent with limited intertumoral heterogeneity. In summary, next-generation sequencing identified limited somatic driver mutations in CIC-DUX4 sarcomas. However, we identified novel, recurrent copy number alterations, including chromosome 1p, which is also the locus of ARID1A. Additional functional work and assessment of larger cohorts are needed to determine the biological and clinical significance of the alterations identified herein.
CIC与DUX4之间的基因融合定义了一类罕见的软组织肉瘤,其在分子水平上了解甚少。先前的核型分析和荧光原位杂交研究支持8号染色体三体作为一种复发性改变;然而,其他驱动性改变在很大程度上尚不清楚。因此,我们使用基于靶向离子激流的多重聚合酶链反应下一代测序技术分析了11个福尔马林固定、石蜡包埋的CIC-DUX4肉瘤组织样本(包括3对样本),以表征409个基因中潜在的体细胞驱动性改变。尽管我们未发现复发性体细胞突变(点突变或插入/缺失),但拷贝数分析显示存在复发性、广泛的拷贝数改变,包括8号染色体增加和1p缺失。在一对样本(未经治疗的原发灶和局部复发切除样本)中,我们仅在局部复发样本中鉴定出相似的拷贝数谱和一个体细胞ARID1A R963X无义突变。在另一对样本(放疗前和放疗后标本)中,我们仅在放疗后复发样本中观察到7号染色体长臂单拷贝缺失,支持其为放疗后的获得性事件。在最后一对样本(近乎同时的化疗后原发灶和远处转移灶)中,分子谱高度一致,与肿瘤间异质性有限相符。总之,下一代测序在CIC-DUX4肉瘤中鉴定出有限的体细胞驱动性突变。然而,我们鉴定出了新的、复发性拷贝数改变,包括1p染色体,其也是ARID1A的基因座。需要进行更多的功能研究和对更大队列的评估,以确定本文所鉴定改变的生物学和临床意义。